Scientific deep-dive
Danuglipron: The Oral GLP-1 That Worked, and That 6 in 10 Did Not Finish
Danuglipron's phase 2b study in 628 adults with obesity produced up to 12.9% weight loss against placebo — and 39.3% of participants completed treatment, with about 38% stopping for adverse events.
Danuglipron is an oral GLP‑1 receptor agonist, and its phase 2b trial in adults with obesity worked: every dose group lost significantly more weight than placebo, up to −12.9% of bodyweight.[1] It also recorded something that matters more than the efficacy figure. Of 626 people who received study treatment, 39.3% completed it. About 38% stopped because of adverse events. A drug that produces that much weight loss and that most people do not finish is a lesson about the difference between working and being usable.
What the trial did
This was a randomized, double-blind, placebo-controlled phase 2b dose-ranging study in adults aged 18 to 75 with obesity and without diabetes. Participants took danuglipron or placebo twice daily for 26 or 32 weeks, with the drug escalated to doses between 40 and 200 mg twice daily over intervals of one, two or four weeks. 628 were randomized; 626 received treatment, 536 of them on danuglipron.[1]
| Result | |
|---|---|
| Weight change vs placebo | −5.0% (90% CI −6.8, −3.2) to −12.9% (90% CI −16.1, −9.5) |
| Completed treatment | 39.3% |
| Discontinued for adverse events | ~38% |
| Discontinued for other reasons | ~22% |
| Most frequent adverse events | Nausea and vomiting, rising with dose |
Twice daily is worth noticing. Every approved GLP‑1 for weight is either a weekly injection or a once-daily oral, and a twice-daily tablet asks more of a person before any side effect arrives. The adverse events were mostly reported as mild, and they still emptied the trial.
Why a completion rate is a result, not a footnote
Weight-loss percentages are usually quoted from the people who finished. If six in ten did not finish, the headline figure describes a minority who tolerated the drug well enough to keep taking it — a group selected, by definition, for tolerating it. That is not fraud and it is not hidden; it is stated in the abstract. It is just routinely dropped from the summary that reaches a reader.
A drug that works for the people who can take it is a different proposition from a drug that works.
The same discipline applies to the drugs you can actually buy. Our page on orforglipron, the other oral small molecule covers the one that reached approval, and the price tracker carries a dated figure for every seller of the injectables.
What this article does not claim
It does not tell you the commercial fate of this compound. Danuglipron is widely discussed as a discontinued program, and we could not source that decision from a primary record in the course of writing this, so we are not asserting it. A trial paper reports a trial. What is on the record here is a phase 2b result and a completion rate, and those stand on their own.
Frequently Asked Questions
References
- 1.Buckeridge C, Cobain S, Bays HE, et al. Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study Diabetes, Obesity & Metabolism. 2025. PMID: 40539310.
Related research
Amycretin: A 24% Weight Figure, and the Trial It Came From
Once-weekly amycretin produced an estimated 24.3% bodyweight reduction at 36 weeks against 1.1% on placebo — from a single-site phase 1b/2a study of 125 people whose primary endpoint was counting adverse events.
5 min read
Bone Density on a GLP-1: The Trial That Compared It Against Exercise
A four-arm randomized trial found liraglutide alone lost hip and spine bone density relative to exercise — while the combination arm lost the most weight and held bone density level with placebo.
7 min read
Dry Mouth on a GLP-1: Three Published Cases, and What to Tell Your Dentist
The published evidence that GLP-1 drugs cause dry mouth is three case reports. Nobody has measured how often it happens — but reduced saliva raises decay risk regardless of cause, which is the part worth acting on.
5 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% were consuming below estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
GLP-1 Drugs After 65: Strength, Not Just Weight
Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite — and no guidelines exist for this age group.
7 min read
GLP-1 Drugs After Menopause: The Group Taking Them Most, Studied Least
One review exists on GLP-1 drugs in peri- and postmenopausal women, and it opens by describing a paucity of data. Here is what has to be borrowed from other populations, and which borrowings hold up.
8 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Trimi Health
Knowing which pharmacy fills the vial — it names VialsRx
Pricing Compare
Get started →ShedRx
Oral orforglipron alongside the injectables
Pricing Compare
Get started →bmiMD
Starting below a standard dose, with microdose tiers
Pricing Compare
Get started →